3-Hydrazino-6-(N-methyl-anilino)-pyridazin | 17259-77-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Hydrazino-6-(N-methyl-anilino)-pyridazin
• 英文别名: (6-hydrazino-pyridazin-3-yl)-methyl-phenyl-amine；6-hydrazino-N-methyl-N-phenylpyridazine-3-amine；6-hydrazinyl-N-methyl-N-phenylpyridazin-3-amine
• CAS: 17259-77-7
• 化学式: C₁₁H₁₃N₅
• 分子量: 215.258
• InChiKey: RCACEWGZYBNDRT-UHFFFAOYSA-N

物化性质

• 沸点：
  366.4±25.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-氯吡啶-2-羧酸 、 3-Hydrazino-6-(N-methyl-anilino)-pyridazin 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 6-chloro-N'-{6-[methyl(phenyl)amino]pyridazin-3-yl}pyridine-2-carbohydrazide
  参考文献：
  名称：

  AGENT INDUCING INCREASE IN BONE MASS

  摘要：

  骨质疏松症等代谢性骨疾病由于骨量减少导致骨强度降低，容易引起腰痛和骨折等疼痛。因此，人们对开发一种可以通过控制整体骨代谢来增加骨量和骨强度的药物非常关注。本发明的制药组合物或组合产品包括源自非生物体的非肽骨细胞分化促进化合物和具有骨吸收抑制作用的双膦酸盐，可作为一种骨量增加诱导剂，通过控制骨代谢来增加骨量和/或骨强度。

  公开号：

  EP1640010A1

文献信息

• Nitrogen-containing heterocyclic compound
  申请人：Igarashi Susumu

  公开号：US20050096322A1

  公开（公告）日：2005-05-05

  As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

  由我们进行的一项努力旨在开发促进成骨细胞功能的骨形成刺激剂的治疗剂，本发明人发现某种含氮杂环化合物对成骨细胞具有强效的骨形成刺激作用，因此可以作为预防或治疗代谢性骨疾病的优秀药物，从而确立了本发明。因此，本发明提供了一种3,6-二取代的1,2,4-三唑并[4,3-b]吡啶嗪化合物或其药学上可接受的盐，以及包含此类化合物和药学上可接受的载体，特别是骨形成剂的药物组合物。
• Agent inducing increase in bone mass
  申请人：Kanoh Hiroyuki

  公开号：US20060173009A1

  公开（公告）日：2006-08-03

  Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase the bone mass and bone strength by controlling the whole bone metabolism. The pharmaceutical composition or combination product of the invention comprising a non-living body-derived non-peptide osteoblast differentiation promoting compound and a bisphosphonate having a bone resorption inhibitory action is useful as a bone mass increasing inducer which can increase the bone mass and/or bone strength by controlling the bone metabolism.

  骨质疏松症和其他代谢性骨疾病由于骨量降低导致骨强度下降，往往会引起腰痛、骨折等疼痛。因此，人们高度关注能够通过控制整个骨代谢增加骨量和骨强度的药物的研制。本发明的药物组合物或联合制品包括非生物体来源的非肽类成骨细胞分化促进化合物和具有骨吸收抑制作用的双磷酸盐，可用作骨量增加诱导剂，可通过调节骨代谢增加骨量和/或骨强度。
• EP1481977
  申请人：——

  公开号：——

  公开（公告）日：——
• US7173033B2
  申请人：——

  公开号：US7173033B2

  公开（公告）日：2007-02-06
• AGENT INDUCING INCREASE IN BONE MASS
  申请人：Astellas Pharma Inc.

  公开号：EP1640010A1

  公开（公告）日：2006-03-29

  Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase the bone mass and bone strength by controlling the whole bone metabolism. The pharmaceutical composition or combination product of the invention comprising a non-living body-derived non-peptide osteoblast differentiation promoting compound and a bisphosphonate having a bone resorption inhibitory action is useful as a bone mass increasing inducer which can increase the bone mass and/or bone strength by controlling the bone metabolism.

  骨质疏松症等代谢性骨疾病由于骨量减少导致骨强度降低，容易引起腰痛和骨折等疼痛。因此，人们对开发一种可以通过控制整体骨代谢来增加骨量和骨强度的药物非常关注。本发明的制药组合物或组合产品包括源自非生物体的非肽骨细胞分化促进化合物和具有骨吸收抑制作用的双膦酸盐，可作为一种骨量增加诱导剂，通过控制骨代谢来增加骨量和/或骨强度。